Development of the suppository form of human immunoglobulin preparation with high titers of antibodies to herpes simplex virus types 1 and 2 for the treatment of chronic forms of herpetic disease.

In spite of the vast arsenal of therapeutic agents, therapy of herpes virus infection (HVI) is very difficult, particularly in pregnant women, newborns and children in the first years of life, as well as in patients with immune deficiency. In this regard, possibility of using immunoglobulins for the treatment of HVI is currently attracting the attention of doctors. The aim of this work was to develop a suppository form of the drug containing donor immunoglobulins with high levels of neutralizing antibodies to herpes simplex virus types 1 and 2 for the treatment of chronic forms of herpetic disease. The study included the following steps: 1) selection of gamma-globulins with high antibody titer for HSV-1 and HSV-2 ELISA test; 2) determination of the level of neutralizing antibodies in the selected series of gamma-globulins in tests in tissue cultures and animals; 3) lyophilization of immunoglobulins; 4) development of the suppository form of the preparation containing gamma-globulin donors with high levels of neutralizing antibodies to HSV-1 and HSV-2; 5) study of the safety of the activity of neutralizing antibodies to HSV-1 and HSV-2 in the suppository form of the drug with hyaluronic acid used as immunomodulator. As the result of this work, immunoglobulin preparation in the suppository form was developed. The developed preparation meets the requirements for safety and efficacy. It is not toxic or pyrogenic. The problems of clinical use of this drug as a method of HVI therapy are discussed.

[Evaluating the effectiveness of Solanum tuberosum shoots extract in experimental ocular herpes].

UNLABELLED: Ocular herpes (OH) is an infectious disease caused by the herpes simplex virus (HSV) characterized by a variable clinical presentation and often accompanied by complications that may lead to deterioration of visual functions, cataract development, or even blindness. Its treatment is arduous. The aim of this work was to evaluate the effectiveness, tolerability, and safety of Panavir eye drops in a rabbit model of OH. MATERIAL AND METHODS: Ocular infection was induced with HSV-1 (EU strain) in grey rabbits (all males, 2.5-3.0 kg) according to the standard technique. The treatment included Panavir-GLA (Panavir-gamma-linolenic acid) and Panavir medications. RESULTS: Panavir eye drops instilled 6 times daily for 8 days showed a pronounced therapeutic effect and prevented the development of severe corneal opacities. The most rapid and significant results were seen in rabbits with epithelial keratitis and those with short-term persistence of the virus. Generally, the effectiveness of Panavir eye drops was comparable with that of the reference drug (Oftalmoferon). Panavir instillations caused no irritation, toxic and/or allergic effects and were well tolerated by the rabbits. CONCLUSION: The data obtained suggest that Panavir eye drops may be included in OH treatment schemes.

[Results of using Solanum tuberosum sprouts extract for the treatment of ophthalmoherpes].

The efficacy, tolerability and safety of the extract of Solanum tuberosum sprouts (Panavir eyedrops) have been studied on the model of ophthalmic disorder in rabbits caused by herpes simplex virus (HSV) type 1. It is established that Panavir applied via 6 instillations per day for a period of days has potent therapeutic efficacy and prevents the development of gross corneal opacity in rabbits. Instillation of Panavir eyedrops does not cause irritation, toxic and allergic effects and are well tolerated by rabbits. The fastest and most pronounced effect of Panavir eyedrops was observed in the treatment of epithelial keratitis, as well as for not prolonged persistence of HSV. The effectiveness of Panavir eyedrops is comparable with that of the reference preparation OphthalmoferonR.